SAN FRANCISCO--(BUSINESS WIRE)--Jennerex Biotherapeutics, a privately-held biotechnology company focused on the development of oncolytic immunotherapies, announced today that management will present at the 33rd Annual Canaccord Genuity Growth Conference 2013, in Boston, Massachusetts. The Jennerex presentation will take place on Thursday, August 15 at 1:30 pm ET/10:30 am PT.
To access a webcast of Jennerex’s presentation, visit http://wsw.com/webcast/canaccord10/JX or the company’s website at www.jennerex.com.
About Jennerex
Jennerex Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of groundbreaking oncolytic immunotherapies for patients with life-threatening cancers. The company’s lead product candidate, Pexa-Vec (JX-594), is in mid-stage clinical development for the treatment of advanced primary liver cancer, colorectal cancer and kidney cancer, and its next generation product candidate, JX-929, is under investigation for a variety of other solid tumors. Jennerex is headquartered in San Francisco and has related research and development operations in Ottawa, Canada and South Korea. For more information about Jennerex, please visit www.jennerex.com.
